Home Categories Biochemical Engineering Pioglitazone
A6816012

Pioglitazone , ≥98% , 111025-46-8

CAS NO.:111025-46-8

Empirical Formula: C19H20N2O3S

Molecular Weight: 356.44

MDL number: MFCD00865504

EINECS: 601-029-7

Pack Size Price Stock Quantity
10MG RMB353.60 In Stock
50MG RMB708.00 In Stock
250MG RMB1276.80 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 183-184 C
Boiling point: 575.4±45.0 °C(Predicted)
Density  1.260±0.06 g/cm3(Predicted)
storage temp.  under inert gas (nitrogen or Argon) at 2-8°C
solubility  DMSO (Slightly, Heated)
form  White to off-white solid.
pka 6.35±0.50(Predicted)
color  White to Off-White
IARC 2A (Vol. 108) 2016

Description and Uses

Pioglitazone is an agonist of the peroxisome proliferator-activated receptor γ (PPARγ; EC50 = ~500-600 nM for both human and murine PPARγ). It is selective for PPARγ over PPARα, exhibiting low level activation of PPARα at 1 μM and 5.4-fold activation at a concentration of 10 μM. Pioglitazone inhibits pyruvate oxidation and glucose production in hepatocytes when used at a concentration of 10 μM. In vivo, pioglitazone (0.3-3 mg/kg per day) reduces hyperglycemia, hyperlipidemia, and hyperinsulinemia in a dose-dependent manner in male Wistar fatty rats. It reduces the number of lesions in a transgenic rat adenocarcinoma of prostate (TRAP) model. Pioglitazone (2.5 mg/kg) also decreases production of neuroinflammatory cytokines and reduces immobility in the forced swim and tail suspension tests in a mouse model of chronic mild stress, indicating antidepressant-like activity that can be reversed by the PPARγ antagonist GW9662 .

antihyperlipidemic, HMGCoA reductase inhibitor

Safety

Symbol(GHS) 
GHS07,GHS08
Signal word  Warning
Hazard statements  H302-H312-H332-H351-H361
Precautionary statements  P280
Hazard Codes  F,C
Risk Statements  11-34
Safety Statements  16-26-36/37/39-45
Hazardous Substances Data 111025-46-8(Hazardous Substances Data)

RELATED PRODUCTS